Best Practice for Diabetic Patients on Hemodialysis 2012

Therapeutic Apheresis and Dialysis

Volumn 19, Issue S1, 2015, Pages 40-66

  Nakao, Toshiyuki ^a   Inaba, Masaaki ^a   Abe, Masanori ^a   Kaizu, Kazo ^a   Shima, Kenji ^a   Babazono, Tetsuya ^a   Tomo, Tadashi ^a   Hirakata, Hideki ^a   Akizawa, Tadao ^a  

^a Scientific Academic Committee of the Japanese Society for Dialysis Therapy   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVERSE DRUG REACTION; ANTIDIABETIC AGENT; BIGUANIDE; DIALYSIS FLUID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; INSULIN; ORAL ANTIDIABETIC AGENT;

ADVERSE EFFECTS; ANALYSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD; BLOOD GAS ANALYSIS; BONE DISEASE; BONE TURNOVER; CALORIC INTAKE; CARDIOVASCULAR MORTALITY; COMPLICATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIAGNOSIS; DIALYSATE; DISEASE CLASSIFICATION; DYSLIPIDEMIA; ETIOLOGY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN TREATMENT; JAPAN; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION; ORTHOSTATIC HYPOTENSION; PHYSIOLOGIC MONITORING; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PREVENTION; PRIORITY JOURNAL; PROCEDURES; RENAL REPLACEMENT THERAPY; THERAPY;

ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANALYSIS; BLOOD; BLOOD GLUCOSE; COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIAGNOSIS; ETIOLOGY; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; KIDNEY FAILURE, CHRONIC; METHODS; MONITORING, PHYSIOLOGIC; PREVENTION AND CONTROL; RENAL DIALYSIS; THERAPY;

EID: 84964304554     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12299     Document Type: Article

References (179)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. Ohkubo Y, Kishikawa H, Araki E etal. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive plasma glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.
5. The Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
7. Bonds DE, Miller ME, Bergenstal RM etal. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
8. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012;35:1897-1901.
9. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995;18:440-447.
10. Chujo K, Shima K, Tada H, Oohashi T, Minakuchi J, Kawashima S. Indicators for plasma glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest 2006;53:223-228.
11. Nakao T, Matsumoto H, Okada T etal. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998;37:826-830.
12. Inaba M, Okuno S, Kumeda Y etal. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903.
13. Peacock TP, Shihabi ZK, Bleyer AJ etal. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-1068.
14. Abe M, Matsumoto K. Glycated hemoglobin or glycated albumin for assessment of glycemic control in dialysis patients with diabetes? Nat Clin Pract Nephrol 2008;4:482-483.
15. Okada T, Nakao T, Matsumoto H etal. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. Intern Med 2011;50:23-29.
16. Okada T, Matsumoto H, Han M etal. Relationship between glycohemoglobin and glycated albumin in chronic dialysis patients. J Jpn Soc Dial Ther 2005;38:31-39. (In Japanese).
17. Freedman BI, Shenoy RN, Planer JA etal. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010;30:72-79.
18. Koga M, Murai J, Saito H, Matsumoto S, Kasayama S. Effects of thyroid hormone on serum glycated albumin levels: study on non-diabetic subjects. Diabetes Res Clin Pract 2009;84:163-167.
19. Koga M, Kasayama S, Kanehara H, Bando Y. CLD (chronic liver disease)-HbA1c as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Res Clin Pract 2008;81:258-262.
20. Shima K, Komatsu M, Kawahara K, Minaguchi J, Kawashima S. Stringent glycemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis. Nephrology 2010;15:632-638.
21. Ricks J, Molnar MZ, Kovesdy CP etal. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes, A 6-year cohort study. Diabetes 2012;61:708-715.
22. Medina RA, Pugh JA, Monterrosa A, Cornell J. Minority advantage in diabetic end-stage renal disease survival on hemodialysis: due to different proportions of diabetic type? Am J Kidney Dis 1996;28:226-234.
23. Wu MS, Yu CC, Yang CW etal. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997;12:2105-2110.
24. Morioka T, Emoto M, Tabata T etal. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001;24:909-913.
25. Oomichi T, Emoto M, Tabata T etal. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis- a 7-year observational study. Diabetes Care 2006;29:1496-1500.
26. Kalantar-Zadeh K, Kopple JD, Regidor DL etal. A1c and survival in maintenance hemodialysis patients. Diabetes Care 2007;30:1049-1055.
27. Ishimura E, Okuni S, Kono K etal. Glycemic control and survival of diabetic hemodialysis patients-importance of lower hemoglobin A1c levels. Diabetes Res Clin Pract 2009;83:320-326.
28. Hayashino Y, Fukuhara S, Akiba T etal. Diabetes, glycemic control and mortality risk in patients on hemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia 2007;50:1170-1177.
29. Suzuki Y, Arakawa M, Gejyo F, Collaborate Study Group. The treatment of the uraemic diabetic. Are we doing enough? A view from Japan. Nephrol Dial Transplant 1995;10(Suppl 7):47-55.
30. Schwedler SB, Metzger T, Schizel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002;62:301-310.
31. Okada T, Nakao T, Matsumoto H etal. Predialysis factors related to prognosis in type 2 diabetic patients on chronic dialysis in Japan. Nephrology 2002;7:250-256.
32. McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002;40:566-575.
33. Williams ME, Lacson E, Jr, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type 1 and type 2 diabetic patients in the U.S.: characteristics, glycemic control, and survival. Kidney Int 2006;70:1503-1509.
34. Fukuoka K, Nakao K, Morimoto H etal. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology 2008;13:278-283.
35. Okada T, Nakao T, Matsumoto H etal. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007;46:807-814.
36. Shurraw S, Majundar SR, Thadhani R, Wiebe N, Tonelli M. Glycemic control and the risk of death in 1484 patients receiving maintenance hemodialysis. Am J Kid Dis 2010;55:875-884.
37. Inaba M, Maekawa K, Okuno S etal. Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol 2012;78:273-280.
38. Freedman BI, Andries L, Shihabi ZK etal. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011;6:1635-1643.
39. National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45(Suppl 3):S1-153.
40. Kazempour-Ardebili S, Lecamwasam VL, Dassnyake T etal. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009;32:1137-1142.
41. Riveline JP, Teynie J, Belmouaz S etal. Glycemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 2009;24:2866-2871.
42. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35:S11-63.
43. Fliser D, Pacini G, Engelleiter R etal. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53:1343-1347.
44. Shinohara K, Shoji T, Emoto M etal. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13:1894-1900.
45. Shen Y, Peak PW, Kelly J. Should we quantify insulin resistance in patients with renal disease? Nephrology 2005;10:599-605.
46. Seino Y, Nanjo K, Tajima N etal. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010;1:2-20.
47. Kaizu K, Uso K, Matsumoto K, Ohnishi Y. Carbohydrate metabolism disorder and malnutrition. J Jpn Soc Dial Ther 2005;38:1256-1257. (In Japanese).
48. Abe M, Kaizu K, Matsumoto K. Evaluation of the hemodialysis-induced changes in plasma glucose and insulin concentrations in diabetic patients: comparison between the hemodialysis and non-dialysis days. Ther Aphaer Dial 2007;11:288-295.
49. Araki H, Daimon S, Matsuda T, Miyazaki R, Fujita Y, Koni I. A case of diabetic ketoacidosis in a hemodialysis patient. J Jpn Soc Dial Ther 1997;30:265-269. (In Japanese).
50. Fujiwara T, Nakayama S, Kato T etal. Onset of diabetic ketoacidosis (DKA) in an insulin-dependent diabetes mellitus (IDDM) patient on maintenance hemodialysis. J Jpn Soc Dial Ther 2000;33(Suppl 1):858. (In Japanese).
51. Kurata K, Hayashi H, Kitagawa W etal. Diabetic ketoacidosis observed in a patient on maintenance hemodialysis. ICU CCU 2001;25(Separate volume):S223-S224.
52. Yamaguchi K, Nakayama S, Ohara M etal. A hemodialysis patient with diabetic ketoacidosis complicated by brain abscess. J Jpn Soc Dial Ther 2002;33(Suppl 1):981. (In Japanese).
53. Shiga N, Ono T, Taneda Y, Umemura S. A case of diabetic ketoacidosis in which hemodialysis was effective in the management of metabolic acidosis. J Jpn Diabet Soc 2002;45:632. (In Japanese).
54. Fujikura J, Yonemitu S, Ariyasu H etal. A case of diabetic ketoacidosis in a hemodialysis patient. J Jpn Diabet Soc 2003;46:484. (In Japanese).
55. Tominaga N, Ohashi S. A case of diabetic ketoacidosis in a maintenance hemodialysis patient. J Osaka Soc Dial Ther 2004;22:102. (In Japanese).
56. Imanaka S. A case of a type 1 diabetic patient on hemodialysis who experienced onset of diabetic ketoacidosis twice. Kidney and Dialysis 2006;60:369-372. (In Japanese).
57. Koyama A, Kurata H, Sawai Y. Onset of diabetic ketoacidosis in a Type 1 diabetic patient on maintenance hemodialysis. J Jpn Soc Dial Ther 2006;39(Suppl 1):845. (In Japanese).
58. Sakuda Y, Nishime K, Nakamura S, Saito T, Sato K, Yoshi S. Factors associated with diabetic ketoacidosis onset in dialysis patients. Okinawa Medical Journal 2006;45:75. (In Japanese).
59. Hashimoto T, Kida Y, Tujinaka K etal. Ketoacidosis in a Type 1 diabetic dialysis patient presenting with a disturbance of consciousness, seizures, and right hemiplegia. J Jpn Diabet Soc 2008;51:560. (In Japanese).
60. Urahama Y, Yoshioka T, Kinashi H, Iida Y. A case of diabetic ketoacidosis in a patient on maintenance hemodialysis. J. Jpn Soc Dial Ther 2009;42(Suppl 1):643. (In Japanese).
61. Taira S, Nakamura H, Nakayama Y etal. Ketoacidosis in an insulin-dependent Type 2 diabetic patient on maintenance hemodialysis. J Jpn Diabet Soc 2010;53(Suppl 1):S-144. (In Japanese).
62. Kato A, Katsuki T, Shibata M etal. Onset of diabetic ketoacidosis in a patient on maintenance hemodialysis. J Jpn Soc Dial Ther 2012;45(Suppl 1):846. (In Japanese).
63. Tomonaga O, Babazono T, Takahashi C, Teraoka S, Ota K, Omori Y. Counterregulatory responses in patients with insulin-dependent diabetes mellitus (IDDM) after successful pancreas transplantation. J Japan Diab Soc 1995;38:839-846. (In Japanese).
64. Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metabolism 2011;12:57-69.
65. Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 2005;16:S7-S10.
66. Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial 2010;23:148-156.
67. Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial 2010;23:163-168.
68. The Japan Diabetes Society. Treatment guide for diabetes 2012-2013 Edited by Japan Diabetes Society, ed. [Accessed August 6, 2014.] Available from URL: http://www.jds.or.jp/
69. Badian M, Korn A, Lehr KH, Malerczyk V, Waldhäusl W. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact 1996;13:69-85.
70. The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S62-S73.
71. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000;23:202-207.
72. Inoue T, Shibahara N, Miyagawa K etal. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003;60:90-95.
73. Nagai T, Imamura M, Iizuka K, Mori M. Hypoglycemia due to nateglinide administration in diabetic patients with chronic renal failure. Diabet Res Clin Pract 2003;59:191-194.
74. Yu L, Lu S, Lin Y, Zeng S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucurosyltransferases. Biochem Pharmacol 2007;73:1842-1851.
75. Abe M, Okada K, Maruyama T, Maruyama N, Maysumoto K. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11:169-176.
76. Abe M, Okada K, Maruyama T, Maruyama N, Maysumoto K. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endcr J 2010;57:581-588.
77. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003;26:886-891.
78. Marbury TC, Ruckle JL, Hatorp V etal. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000;67:7-15.
79. Schumacher S, Abbasi I, Weise D, Sattler K, Sieber J, Hasslacher C. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Pharmacol 2001;57:147-152.
80. Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in type 2 diabetic patients on haemodialysis. Clin Nephrol 2007;68:287-294.
81. The United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive plasma glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854-865.
82. Selvin E, Bolen S, Yeh HC etal. Cardiovascular outcomes in trials of oral diabetes medications. Arch Intern Med 2008;168:2070-2080.
83. Saenz A, Fermamdez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(20):CD002966.
84. Lalau JD, Andrejak M, Moriniere P etal. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989;27:285-288.
85. Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009;37:2191-2196.
86. Dormandy JA, Charbonnel B, Eckland DJ etal. The PROactive investigators: secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macro Vascular Events): a randomized controlled trial. Lancet 2005;366:1279-1289.
87. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188.
88. Nesto RW, Bell D, Bonow RQ etal. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the AHA and ADA. Circulation 2003;108:2941-2948.
89. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
90. Idris I, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 2007;9:153-165.
91. Richter B, Banderia-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;(16):CD006739.
92. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-658.
93. Partley RE. Alogliptin: a new. highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009;10:503-512.
94. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051-2072.
95. Lukashevich V, Schweizer A, Shao Q, Grooop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo controlled trial. Diabetes Obes Metab 2011;13:947-954.
96. Ito M, Abe M, Okada K etal. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011;58:979-987.
97. Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of Bl 1356, an inhibitor of dipeptidylpeptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-1178.
98. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantage of α-glucosidase inhibitor as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83:1515-1522.
99. Herz M, Sun B, Milicevic Z etal. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60-80 years of age with type 2 diabetes mellitus. Clin Ther 2002;24:73-86.
100. Pratley RE, Rosenstock J, Pi-Sunyer FX etal. Management of type 2 diabetes in treatment-naïve elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30:3017-3022.
101. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin 1989;18:163-183.
102. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y. Drug-induced hypoglycemia in 102 diabetic patients. Arch Intern Med 1999;159:281-284.
103. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors or hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157:1681-1686.
104. Murata GH, Duckworth WC, Shah JH, Wendel CS, Hoffman RM. Factors affecting hypoglycemia awareness in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Res Clin Pract 2004;65:61-67.
105. The Japan Diabetes Society. Evidence-Based Practice Guideline for the Treatment of Diabetes in Japan 2010. Tokyo: Nankodo Co., Ltd., 2010. (In Japanese).
106. Home PD, Lindholm A, Riis A, The European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term plasma glucose control in type 1 diabetes mellitus : a randomized controlled trial. Diabet Med 2000;17:762-770.
107. Gale EAM, The U.K. Trial Group. A randomized controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med 2000;17:209-214.
108. Kuzuya T, Kosaka K, Akanuma Y etal. Comparison between insulin lispro and fast-acting human insulin products in type 1 and type 2 diabetic patients with frequent injections-domestic clinical testing results. J Clin Therap Med 2000;16:1613-1630. (In Japanese).
109. Iwamoto Y, Akanuma Y, Niimi H etal. Comparison between insulin aspart and fast-acting human insulin products in six patients with insulin-dependent diabetes mellitus (IDDM) on basal-bolus insulin therapy-domestic phase-III testing results. J Jpn Diabet Soc 2001;44:799-811. (In Japanese).
110. Abe M, Kaizu K, Matsumoto K. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysis fluid with or without glucose. Ther Apher Dial 2007;11:280-287.
111. Abe M, Okada K, Mtsumoto K. Plasma insulin and C-peptide concentrations in diabetic patients undergoing hemodialysis: comparison with fine types of. Diabetes Res Clin Pract 2008;82:e17-19.
112. The Diabetes Control and Complication Trial (DCCT) Research Group. The early worsening of diabetic retinopathy in the Diabetes Control and Complication Trial. Arch Ophthalmol 1998;116:874-886.
113. Takahashi Y, Takayama S, Ito T etal. Clinical features of eighty-six diabetic patients with post-treatment painful neuropathy. J Jpn Diabet Soc 1998;41:165-170. (In Japanese).
114. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905.
115. Linnebjerg H, Kothare PA, Park S etal. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-327.
116. AstraZeneca K.K. Byetta (exenatide injection) prescribing information. 2014. [Accessed March 3, 2014.] Available from URL: http://med.astrazeneca.co.jp/product/BE.html#
117. Ministry of Health, Labour and Welfare. Dietary Reference Intakes for Japanese (2010 Edition). Tokyo: Dai-ichi Shuppan Co., Ltd., 2009. (In Japanese).
118. Monteon FJ, Laidlaw SA, Shaib JK etal. Energy expenditure in patients with chronic renal failure. Kidney Int 1986;30:741-747.
119. Schneeweiss B, Graninger W, Stockenhuber F etal. Energy metabolism in acute and chronic renal failure. Am J Clin Nut 1990;52:596-601.
120. Ikizler TA, Wingard RL, Sun M etal. Increased energy expenditure in hemodialysis patients. J Am Soc Nephrol 1996;7:2646-2653.
121. Avesani CM, Cuppari L, Silva AC etal. Resting energy expenditure in pre-dialysis diabetic patients. Nephrol Dial Transplant 2001;16:556-565.
122. O'Sullivan AJ, Lawson JA, Chan M etal. Body composition and energy metabolism in chronic renal insufficiency. Am J Kidney Dis 2002;39:369-375.
123. Avesani CM, Draibe SA, Kamimura MA etal. Decreased resting energy expenditure in non-dialyzed chronic kidney disease patients. Nephrol Dial Transplant 2004;19:3091-3097.
124. Cuppani L, de Carvalho AB, Avesani CM etal. Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism. J Am Soc Nephrol 2004;15:2933-2939.
125. Bazanelli AP, Kamimura MA, da Siliva CB etal. Resting energy expenditure in peritoneal dialysis patients. Perit Dial Int 2006;26:697-704.
126. Kogrima M, Sakaguchi K, Nishino K etal. Low resting energy expenditure in middle-aged and elderly hemodialysis patients with poor nutritional status. J Med Invest 2006;53:34-41.
127. Kamimura MA, Draibe SA, Avesani CM etal. Resting energy expenditure and its determinants in hemodialysis patients. Eur J Clin Nutr 2007;61:362-367.
128. Horacek J, Sulkova SD, Fortova M etal. Resting energy expenditure and thermal balance during isothermic and thermoneutral hemodialysis-heat production dose not explain increased body temperature during haemodialysis. Nephrol Dia Transplant 2007;22:3553-3560.
129. Hori S. Classification of diabetic retinopathy: re-evaluation of Fukuda's classification part 1. Folia Opthalmol Jpn 1989;40:205-213. (In Japanese).
130. Davis MD, Fisher MR, Gangnon RE etal. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998;39:233-252.
131. Nawrocki J, Chrzanowski W, Koch D, Dziegielewski K. Vitreoretinal surgery in diabetic patients on hemodialysis. Eur J Ophthalmol 1997;7:283-287.
132. Hayashi H, Kurata Y, Imanaga Y, Goya K, Oshima K. Vitrectomy for diabetic retinopathy in patients undergoing hemodialysis for associated end-stage renal failure. Retina 1998;18:156-159.
133. El Shahat Y, Rottembourg J, Bellio P, Guimont MC, Rousselie F, Jacobs C. Visual function can be preserved in insulin-dependent diabetic patients treated by maintenance hemodialysis. Proc Eur Dial Transplant Assoc 1980;17:167-172.
134. Diaz-Buxo JA, Burgess WP, Greenman M, Chandler JT, Farmer CD, Walker PJ. Visual function in diabetic patients undergoing dialysis: comparison of peritoneal and hemodialysis. Int J Artif Organs 1984;7:257-262.
135. Takeda M, Kihara A, Aizawa F etal. Effect of dialysis therapy on diabetic retinopathy. Ophthalmology 1989;31:849-854. (In Japanese).
136. Kure M, Shimizu Y, Saito K. Effect of hemodialysis on vision and retinopathy in patients with diabetic nephropathy. Folia Ophthalmol Jpn 1991;42:1060-1063. (In Japanese).
137. Tokuyama T, Ikeda T, Ishikawa H etal. Diabetic retinopathy in hemodialysis patients. J Eye 1994;11:1069-1072. (In Japanese).
138. Ishii A, Babazono T, Haruyama K etal. Trends over time for diabetic retinopathy in diabetic patients with end-stage renal disease. J Japan Diabetes Soc 2002;45:737-742. (In Japanese).
139. Ichikawa K. Complications in dialysis patients with diabetes. Jpn J Clin Dial 2001;17:91-95. (In Japanese).
140. Japanese Society for Dialysis Therapy. Clinical guidelines for the evaluation and treatment of cardiovascular complications in hemodialysis patients. J Jpn Soc Dial Ther 2011;44:337-425. (In Japanese).
141. Japanese Society for Dialysis Therapy. Report of statistical survey committee. June 20, 2004. (In Japanese).
142. Kimoto E, Shoji T, Shinohara K etal. Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J Am Soc Nephrol 2006;17:2245-2252.
143. Ishimura E, Shoji T, Emoto M etal. Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am J Kidney Dis 2001;38:S186-190.
144. Sarnak MJ, Levey AS, Schoolwerth AC etal.; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
145. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
146. Ohtake T, Kobayashi S, Moriya H etal. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005;16:1141-1148.
147. Joki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 1997;12:718-723.
148. The Japanese Society of Hypertension. Guidelines for the Management of Hypertension (JSH2009). Tokyo, Japan: Life Science Publishing Co., Ltd., 2009. (In Japanese).
149. Japan Atherosclerosis Society. Guideline for prevention of atherosclerotic cardiovascular diseases, 2007 edition. (In Japanese).
150. Nakai S, Shinzato T, Nagura Y etal. An overview of regular dialysis treatment in Japan as of (Dec. 31, 2001). Ther Apher Dial 2004;8:3-32.
151. Okuno S, Ishimura E, Kitatani K etal. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 2007;49:417-425.
152. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
153. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
154. Ishimura E, Okuno S, Kitatani K etal. Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients-importance of glycaemic control. Diabetologia 2002;45:1446-1448.
155. Inaba M, Nagasue K, Okuno S etal. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 2002;39:1261-1269.
156. Kurz P, Monier-Faugere MC, Bognar B etal. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994;46:855-861.
157. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J am Soc Nephrol 2008;19:1827-1835.
158. Hase H, Tsunoda T, Tanaka Y etal. Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int 2006;70:1142-1148.
159. Shoji T, Emoto M, Shinohara K etal. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001;12:2117-2124.
160. Nishizawa Y, Shoji T, Maekawa K etal. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2003;41(3 Suppl 1):S76-79.
161. Nitta K, Akiba T, Suzuki K etal. Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 2004;7:527-533.
162. Adragao T, Pires A, Branco P etal. Ankle-brachial index, vascular calcifications and mortality in dialysis patients. Nephrol Dial Transplant 2012;27:318-325.
163. Ramsey DE, Manke DA, Sumner DS. Toe blood pressure. A valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease. J Cardiovasc Surg 1983;24:43-48.
164. Nakai S, Wada A, Kitaoka T etal. Overview of regular dialysis treatment in Japan (as of 31 Dec. 2014). Ther Apher Dial 2006;10:476-497.
165. Wanner C, Krane V, Marz W etal. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
166. März W, Genser B, Drechsler C etal.; German Diabetes and Dialysis Study Investigators. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011;6:1316-1325.
167. Lepäntalo M, Fiengo L, Biancari F. Peripheral arterial disease in diabetic patients with renal insufficiency: a review. Diabetes Meratb Res Rev 2012;28(Suppl 1):40-45.
168. Nakai S, Masakane I, Akiba T etal. An overview of regular dialysis treatment in Japan (as of Dec. 31, 2005). J Jpn Soc Dial Ther 2007;40:1-30. (In Japanese).
169. Fishbane S, Youn S, Flaster E, Adam G, Maesaka JK. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis 1996;27:668-672.
170. Ishida H, Seino Y, Taminato T etal. Circulating levels and bone contents of bone _-carboxyglutamic acid containing protein are decreased in streptozotocin-induced diabetes: possible marker of diabetic osteopenia. Diabetes 1988;37:702-706.
171. Martinez I, Saracho R, Moina I, Montenegro J, Llach F. Is there a lesser hyperparathyroidism in diabetic patients with chronic renal failure? Nephrol Dial Transplant 1998;12(Suppl 3):S9-S11.
172. Yoshida O, Inaba M, Terada M etal. Impaired response of human osteosarcoma (MG-63) cells to human parathyroid hormone induced by sustained exposure to high glucose. Miner Electrolyte Metab 1995;21:201-204.
173. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 1995;44:775-782.
174. Rico H, Hernandez ER, Cabranes JA, Gomez-Castresana F. Suggestion of a deficient osteoblastic function in diabetes mellitus. The possible cause of osteopenia in diabetics. Calcif Tissue Int 1989;45:71-73.
175. Bouillon R, Bex M, Van Herck E etal. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 1995;80:1194-1202.
176. Sugimoto T, ed. Committee for Evaluation of Fracture Risk in Association with Lifestyle-Related Diseases, Japan Osteoporosis Society. Clinical Guidelines for Fracture Risk in Association with Lifestyle-Related Diseases. Tokyo, Japan: Life Science Publishing Co., Ltd., 2011. (In Japanese).
177. Inaba M, Okuno S, Kumeda Y, Yamakawa T, Ishimura E, Nishizawa Y. Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 2005;76:256-260.
178. Yamada S, Inaba M, Kurajoh M etal. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf) 2008;69:189-196.
179. Shidara K, Inaba M, Okuno S etal. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 2008;82:278-287.